Stereotactic body radiotherapy for operable, early stage non-small cell lung cancer—let’s all take a deep breath

Eric B. Howell, Kathleen S. Berfield, Douglas E. Wood

Abstract

In spite of a federally mandated emphasis on smoking cessation and primary prevention, lung cancer remains by far the most common cause of cancer death and carries a 5-year survival rate (~18%) that is far lower than that of other leading cancers (1).